# Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

> **NCT03346668** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 5 (actual)

## Conditions studied

- Scarring Alopecia
- Frontal Fibrosing Alopecia
- Lichen Planopilaris
- Central Centrifugal Cicatricial Alopecia
- Central Centrifugal Scarring Alopecia

## Interventions

- **DRUG:** Topical gabapentin

## Key facts

- **NCT ID:** NCT03346668
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-28
- **Primary completion:** 2021-10-11
- **Final completion:** 2021-10-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346668, "Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03346668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*